Articles tagged "Hepatitis C"

2018 American Transplant Congress
Effect of Direct-Acting Hepatitis C Treatment Regimens on Calcineurin Inhibitors in Liver and Kidney Transplant Patients
M. Laub, J. Byrns, M. Harris, C. Berg, S. Sanoff.
Duke University Hospital, Durham, NC.
Background: It has been suggested that treatment with direct-acting antivirals (DAA) for hepatitis C virus (HCV) may decrease calcineurin inhibitor (CNI) concentrations. The purpose of…
2018 American Transplant Congress
Use of Hepatitis-C Treatments after Kidney Transplantation: Impact of the Direct-Acting Antiviral Era
K. Lentine, D. Axelrod,² R. Bloom,³ H. Xiao,¹ D. Segev,⁴ T. Alhamad,⁵ H. Randall,¹ R. Ouseph,¹ V. Dharnidharka,⁵ D. Brennan,⁴ N. Lam,⁶ A. Naik,⁷ G. Hess,⁸ B. Kaiske,⁹ M. Schnitzler.¹
¹Saint Louis U, St. Louis; ²Lahey, Burlington; ³U Penn, Philadelphia; ⁴Johns Hopkins, Baltimore; ⁵Washington U, St. Louis; ⁶U Alberta, Edmonton, Canada; ⁷U Michigan, Ann Arbor; ⁸Hennepin, Minneapolis; ⁹Symphony Health, Conshohocken.
Hepatitis C virus (HCV) infection in kidney transplant (KTx) donors or recipients has correlated with adverse outcomes, partly due to limited treatment options. Development of…
2018 American Transplant Congress
HCV Ab+/NAT- Organ Donors, and the Challenges of 'Eclipse Windows': Analysis of the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee (DTAC)
C. Wolfe, S. Tlusty, G. Vece, R. Sawyer, R. Bag, G. Berry, J. Bucio, L. Danziger-Isakov, D. Goldberg, C. Ho, D. Florescu, D. Klassen, R. La Hoz, K. Lilly, A. Mehta, M. Malinis, M. Nalesnik, N. Theodoropoulos, P. Wood, M. Michaels.
DTAC, United Network for Organ Sharing, Richmond, VA.
Introduction: In 2017, CDC reported new hepatitis C (HCV) cases had tripled over 5 years, mainly due to intravenous drug use (IVDU). As the proportion…
2018 American Transplant Congress
Outcomes of Antiviral Treatment (AVT) in Hepatitis C Virus (HCV) Liver Transplant (LT) Patients off Immunosuppression (IS) in Direct Acting Antivirals (DAA) Era
E. Agudelo,^1,2 I. Campos-Varela,³ N. Terrault.^1,2
¹Medicine, University of California San Francisco, San Francisco, CA; ²Surgery, University of California San Francisco, San Francisco, CA; ³Internal Medicine, Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
Background: Clearance of HCV under AVT, including DAAs, has been associated with higher risk of rejection, possibly due to the changing immunological environment within the…
2018 American Transplant Congress
Hidden Risk of Liver Transplantation for Nonalcoholic Steatohepatitis: A Propensity Score Matched Study
S. Nagai,¹ R. Schilke,¹ M. Safwan,¹ M. Rizzari,¹ K. Collins,¹ A. Yoshida,¹ M. Abouljoud,¹ D. Moonka.²
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI; ²Gastroenterology, Henry Ford Hospital, Detroit, MI.
Aim: There is a recent shift in the number of liver transplants (LT) performed in patients with hepatitis C (HCV) to those with non-alcoholic steatohepatitis…
2018 American Transplant Congress
Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation
A. Kwong,¹ A. Wall,² M. Melcher,² U. Wang,³ A. Ahmed,¹ K. Khush,³ A. Subramanian,³ J. Tan,³ P. Kwo.¹
¹Gastroenterology and Hepatology, Stanford University, Palo Alto, CA; ²Surgery, Stanford University, Palo Alto, CA; ³Stanford University, Palo Alto, CA.
Background: In the context of organ shortage, the opioid epidemic, and the advent of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), more…
2018 American Transplant Congress
Treatment and Outcomes of Orthotopic Liver Transplant Patients Secondary to Hepatitis C Virus: A Single Center Experience
T. Chen,¹ M. Moaddab,¹ B. Pierce,¹ R. Ghobrial.²
¹Department of Pharmacy, Houston Methodist Hospital, Houston, TX; ²Department of Surgery, Houston Methodist Hospital, Houston, TX.
Background: Treatment of acute cellular rejection (ACR) in patients with orthotopic liver transplantation (OLT) secondary to hepatitis C virus (HCV) remains a major challenge due…
2018 American Transplant Congress
Transplanting Kidneys from HCV-Infected Donors into HCV-Negative Recipients: Longer-Term and Extended Results of the THINKER Trial
D. Goldberg,¹ E. Blumberg,¹ P. Abt,¹ M. Levine,¹ P. Porrett,¹ A. Naji,¹ S. Nazarian,¹ D. Sawinski,¹ J. Trofe-Clark,¹ V. Van Deerlin,¹ C. Gentile,¹ J. Smith,¹ M. Kaminski,¹ A. Sicilia,¹ R. Hasz,² L. Suplee,² R. Reddy,¹ R. Bloom,¹ P. Reese.¹
¹University of Pennsylvania, Philadelphia; ²Gift of Life, Philadelphia.
Background: In 2016, 800 kidneys from HCV+ deceased donors were discarded. Short-term (6-month) data from the first 10 subjects in the THINKER-1 trial (NCT02743897; funder:…
2018 American Transplant Congress
Single-Center Experience with Sofosbuvir-Based HCV Treatment after Kidney Transplantation
V. Garcia, G. Meinerz, C. da Silva, R. Bruno, E. Keitel.
Nephrology and Kidney Transplant Department, ISCMPA, Porto Alegre, Brazil.
Chronic hepatitis C (HCV) infection is an important clinical challenge after kidney transplantation. This is the initial report of a single-center experience with sofosbuvir-based HCV…
2018 American Transplant Congress
Hepatitis C Recurrence after Liver Transplant: A Comparison of Antibody Induction versus No Antibody Induction
S. Patel, J. Jin, E. Benedetti, P. West-Thielke.
University of Illinois Hospital and Health Sciences System, Chicago.
Background: Hepatitis C virus (HCV) recurrence after orthotopic liver transplant (OLT) is universal and exhibits accelerated progression to cirrhosis. Progression can be mitigated by new…